[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Indiana University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":640},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,177,0,25,[9,44,68,89,109,129,154,180,200,250,275,304,346,374,400,419,440,457,474,509,531,552,575,598,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644977","overground-virtual-reality-vr-gait-rehabilitation-for-stroke-100644977",false,"NCT07676578","Overground Virtual Reality (VR) Gait Rehabilitation for Stroke","Investigating the Feasibility and Translational Therapeutic Benefits of Overground, Fully Immersive Virtual Reality (VR) Gait Rehabilitation Therapies for Stroke Survivors","Inclusion Criteria:\n\n* Diagnosis: Anischemic or hemorrhagic stroke verified by imaging, confirmed by the patient's physician, and 1-6 months post-stroke (subacute phase)\n* Motor Impairment Level: Functional Ambulation Category (FAC) 3-5, showing moderate impairment while still allowing safe participation in gait tasks.\n* Cognitive Function: Mini-Mental State Examination (MMSE) score ≥ 24 or Montreal Cognitive Assessment (MoCA) score \\>= 20, indicating sufficient cognitive function to participate in the study.\n* Exercise Clearance: Approval from a physician for participation in exercise- and VR-based interventions.\n* Rehabilitation Need: 10-Meter Walk Test \\\u003C1.0 m\u002Fs, as timed by a PT during screening, indicating a need for functional rehabilitation.\n* Consent: Must be able to provide informed consent for themselves.\n\nExclusion Criteria:\n\n* Participants with uncontrolled cardiovascular, orthopedic, or metabolic conditions or unstable medication regimens that could interfere with their participation in the study.\n* Any comorbidity that could interfere with walking or gait training.\n* Participation in robot- or VR-assisted gait training within the last 6 months.\n* Intolerance to virtual reality environments or motion simulation.\n* Severe cognitive, visual, or hearing impairments where the participant cannot follow the therapist's instructions.\n* Any other condition deemed unsafe or confounding by investigator, such as pre-existing neurological conditions unrelated to stroke (e.g. Parkinson's, multiple sclerosis), unmanaged pain medications, or acute medical events during the screening period (e.g. recurrent stroke, hospitalization).\n* Individuals who score a 12 or higher on the Disability Rating Scale.\n* Recent Therapy: Participants should not have received physical therapy (PT) within the last month.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to evaluate a new virtual reality (VR)-based rehabilitation program designed to help stroke survivors improve their walking abilities in real-world settings. By comparing immersive VR-assisted overground gait therapy to contemporary non-immersive, treadmill-based VR therapy (i.e., C-Mill), the investigators aim to determine its effectiveness in enhancing mobility and quality of life for stroke survivors.",[27],"Stroke",[29,30,27],"Gait Training","Virtual Reality","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":21},"2026-08",{"date":39,"type":21},"2027-08",{"name":41,"class":42},"Indiana University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100644872","safety-and-efficacy-of-adjunct-therapies-in-adults-with-type-1-diabetes-multicenter-registry-study-100644872","NCT07676565","Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study","Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study","ATT1D","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Clinical diagnosis of T1D\n* GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week\n* Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* No exclusion criteria other than those not meeting inclusion criteria above",{"count":53,"type":21},300,"1 Year","OBSERVATIONAL","This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.",[58],"Type 1 Diabetes","2026-06-24",{"date":61,"type":35},"2026-06-30",{"date":63,"type":35},"2026-03-24",{"date":65,"type":21},"2028-04",{"name":41,"class":42},7,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100643731","the-effect-of-respiratory-muscle-training-on-cognitive-performance-100643731","NCT07637331","The Effect of Respiratory Muscle Training on Cognitive Performance","Inclusion Criteria:\n\n* 18-40 years old\n* Body mass index \\\u003C30 kg\u002Fm2\n* Naïve to IMT\n* \\>75% of predicted forced expiratory volume in 1 second (FEV1) \u002F forced vital capacity (FVC) (FEV1\u002FFVC)\n* Access to smart phone or tablet with internet\n\nExclusion Criteria:\n\n* Diagnosed:\n\n  * Cardiovascular disease\n  * Respiratory disease (including asthma)\n  * Metabolic disease\n  * Currently pregnant\n  * Unable to adhere to the IMT protocol\n* Answering 'yes' to any of the questions on page one of the PAR-Q+\n* Abnormal cognition assessed via the Montreal Cognitive Assessment (score of 25 or less)\n* Self-reported color blindness\n* Significant acute or chronic medical, neurologic, or illness in the participant that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability of the participant to complete the study, and\u002For compromise the objectives of the study",true,"40 Years",{"count":77,"type":21},32,[24],"Determine if exercise training for the respiratory muscles improves cognitive performance during periods when breathing against a resistance.",[81],"Respiratory Muscle Training",{"date":83,"type":35},"2026-06-26",{"date":85,"type":35},"2026-03-27",{"date":87,"type":21},"2027-04",{"name":41,"class":42},{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":43},"100595933","overground-virtual-reality-vr-gait-rehabilitation-for-traumatic-brain-injury-tbi-100595933","NCT07038889","Overground Virtual Reality (VR) Gait Rehabilitation for Traumatic Brain Injury (TBI)","Investigating the Feasibility and Translational Therapeutic Benefits of Overground, Fully Immersive Virtual Reality (VR) Gait Rehabilitation Therapies for Individuals With Traumatic Brain Injury (TBI)","Inclusion Criteria:\n\n* Diagnosis: A confirmed diagnosis of traumatic brain injury (TBI), confirmed by the referring physician.\n* Cognitive Function: Mini-Mental State Examination (MMSE) score ≥ 24 or Montreal Cognitive Assessment (MoCA) score ≥ 20, indicating sufficient cognitive function to participate in the study.\n* Exercise Clearance: Approval from a physician for participation in exercise-based interventions.\n* Rehabilitation Need: Demonstrates a need for functional rehabilitation.\n* Recent Therapy: Participants should not have received physical therapy (PT) within the last month.\n* Consent: Must be able to provide informed consent for themselves.\n\nExclusion Criteria:\n\n* Participants with unstable medication regimens that could interfere with their participation in the study.\n* Any comorbidity that could interfere with walking or gait training.\n* Participation in VR-assisted gait training within the last 6 months.\n* Intolerance to virtual reality environments or motion simulation.\n* Severe cognitive, visual, or hearing impairments where the participant cannot follow the therapist's instructions.\n* More than 135 kg total body weight.\n* More than 2.00 meters in body height.\n* Presence of open skin lesions or bandages in areas that would come into contact with the harness.\n* Functional Ambulation Category (FAC): Participants with an FAC score of less than 2 indicate they require physical support from more than one person to walk.\n\nClarification:\n\n\\- The diagnosis of TBI can be confirmed by their physician or a physical therapist referring to the patient. If a physical therapist makes the referral, the diagnosis must still be officially confirmed by a physician to ensure it meets the study's medical criteria.",{"count":20,"type":21},[24],"The purpose of this study is to evaluate a new virtual reality (VR)-based rehabilitation program designed to help individuals with traumatic brain injury (TBI) improve their walking abilities in real-world settings. By comparing immersive VR-assisted overground gait therapy to contemporary non-immersive, treadmill-based VR therapy (i.e., C-Mill), the investigators aim to determine its effectiveness in enhancing mobility and quality of life for TBI patients.",[100],"Traumatic Brain Injury",[29,30,100],"NOT_YET_RECRUITING",{"date":83,"type":35},{"date":105,"type":21},"2026-07",{"date":107,"type":21},"2027-06",{"name":41,"class":42},{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":43},"100548372","the-prevalence-of-neuropathic-pain-pathophysiology-associated-with-ankle-fracture-100548372","NCT06420141","The Prevalence of Neuropathic Pain Pathophysiology Associated With Ankle Fracture","AFNP","Fracture Group:\n\nInclusion Criteria:\n\n1. 18-85 years old\n2. an isolated rotational ankle (AO\u002FOTA 44 types A-C) fracture that is treated operatively\n3. Abbreviated Injury Scale \\\u003C 3 for non-extremity body systems\n4. can speak, read, and understand English\n\nExclusion Criteria:\n\n1. treated for a chronic pain condition prior to their qualifying injury\n2. on a pain contract\n3. pathologic fracture\n4. Daily use of gabapentin or opiods prior to enrollment\n\nControl Group:\n\nInclusion Criteria:\n\n1. 18-85 years of age\n2. can speak, read, and understand English\n\nExclusion Criteria:\n\n1. Chronic pain or an ongoing acute pain condition\n2. Currently or have previously sustained a bone fracture\n3. Current Pain medication usage\n4. Any previous orthopaedic surgical procedures\n5. Must have been free of any surgeries for at least 5 years\n6. Peripheral neuropathy\n7. Individuals having had a major surgery or a major disease or condition, as determined by the PI, such as cardiovascular disease, metabolic disorders, renal disease, neurological disorders, or severe psychiatric conditions.","85 Years",{"count":118,"type":21},250,"This application addresses the Peer Reviewed Medical Research Program Investigator-Initiated Research Award FY21 W81XWH-22-CPMRP-IIRA area of Chronic Pain Management Research Program- The investigators will utilize subjects who have sustained ankle fractures and may develop chronic pain following bone union. No attempt will be made to affect the experimental outcome in the subjects. This study will adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of research.",[121],"Neuropathic Pain","2026-06-23",{"date":83,"type":35},{"date":125,"type":35},"2024-01-03",{"date":127,"type":21},"2027-12-31",{"name":41,"class":42},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":43},"100519625","automated-assistive-non-contact-sleep-quality-monitor-for-individuals-with-alzheimers-disease-100519625","NCT06045988","Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease","Inclusion Criteria:\n\n* Diagnosis of Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementias (ADRD)\n* Residents of long-term care (LTC) facility study site location for a minimum of 30 days.\n* Willingness to consent to study or when a potential participant lacks decision making capacity (determined by LTC facility clinical provider) willingness of a Legally Authorized Representative (LAR) to consent to study participation on potential participant's behalf.\n\nExclusion Criteria:\n\n* Currently on hospice",{"count":136,"type":21},100,[24],"This study seeks to evaluate the utility and efficacy of the Non-Contact Sleep Quality Monitor System when used to monitor the sleep quality of individuals living in long-term care (LTC) with either Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementia (ADRD). This before-after comparison trial will be conducted in several LTC facilities to evaluate the effect access to System Sleep Quality Data has on documentation of sleep disorders or treatments and sleep quality change over time for AD\u002FADRD participants in the intervention group as compared to the control group.\n\nAll subjects will undergo sleep quality monitoring for 4-weeks. At the end of the first 2-weeks, research staff and LTC facility staff and medical providers will receive access to sleep monitoring data. We hypothesize that when real-time System Sleep Data is shared with LTC staff or healthcare providers, that sleep disturbances will be more readily detected, leading to timelier, better tailored treatment interventions for sleep disturbances, thereby improving sleep quality and decreasing daytime physical inactivity.",[140,141,142],"Alzheimer Disease","Dementia","Sleep Disturbance",[144,145,146,141,147,148],"Sleep Assessment","Sleep Disorder","Technology","Long-Term Care","Sleep Monitoring",{"date":83,"type":35},{"date":105,"type":21},{"date":152,"type":21},"2026-12",{"name":41,"class":42},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":162,"minAge":18,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100448849","intensive-glycemic-targets-in-overweight-and-obese-women-with-gestational-diabetes-100448849","NCT05124808","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes Mellitus: A Multicenter Randomized Trial","iGDM","Inclusion Criteria:\n\n* Pregnant women between the ages of 18-45\n* Singleton gestation\n* Gestational age between 12 0\u002F7-32 6\u002F7 weeks' gestation with gestational diabetes diagnosed during this time frame using either a 50g 1-hr GCT ≥200 mg\u002FdL or two or more abnormal values on a 100g OGTT using the Carpenter-Coustan Criteria\n* Overweight or obese BMI at the first prenatal visit (BMI ≥25 kg\u002Fm2 or ≥23 kg\u002Fm2 in Asian Americans)\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with members of the study team, despite the presence of an interpreter\n* Planned delivery at a non-study affiliated hospital\n* Known renal disease with a baseline creatinine \\>1.5 mg\u002FdL\n* Significant fetal anomalies diagnosed prior to study enrollment (these will include anomalies such as gastroschisis, spina bifida, complex congenital heart disease, or serious karyotypic anomalies that may lead to early delivery or increased risk of neonatal death)\n* Oral or IV\u002FIM steroid use within 7 days of study enrollment","FEMALE","45 Years",{"count":165,"type":21},828,[24],"This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.",[169,170,171],"Gestational Diabetes","Pregnancy, High Risk","Overweight and Obesity","2026-06-22",{"date":59,"type":35},{"date":175,"type":35},"2022-03-01",{"date":177,"type":21},"2026-12-31",{"name":41,"class":42},5,{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100465905","survivorship-plan-health-record-sphere-implementation-trial-100465905","NCT05346796","Survivorship Plan HEalth REcord (SPHERE) Implementation Trial","SPHERE","Inclusion Criteria:\n\n1. Patients must be 18 years or older at the time of consent\n2. Patients must have regular (at least weekly) access to an internet connection, whether at home or elsewhere (family or friend).\n3. Diagnosis of colon or rectal cancer, Stages I, II, or III (AJCC, American Joint Committee on Cancer) and have undergone initial curative-intent therapy for their CRC diagnosis within the past 12 months.\n4. English-speaking\n\nExclusion Criteria:\n\n1. Patient will be excluded if they have had recurrence of their colorectal cancer.\n2. Patient's with severe cognitive impairment\n3. Patient's with schizophrenia or other psychosis\n4. Patients currently in hospice care","99 Years",{"count":118,"type":21},[24],"To understand the effectiveness and implementation of the SCP-PHR, we will conduct a hybrid type 1 effectiveness-implementation trial consisting of the following components: (A) a randomized clinical effectiveness trial, and (B) a mixed methods implementation study.",[192],"Cancer","2026-06-19",{"date":59,"type":35},{"date":196,"type":35},"2022-09-09",{"date":198,"type":21},"2027-05-31",{"name":41,"class":42},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":241,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":43},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","14 Years","17 Years",{"count":211,"type":21},80,[24],"This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240],"Cannabis Use","Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[242,225,233],"Cannabis","2026-06-18",{"date":172,"type":35},{"date":246,"type":35},"2026-06-15",{"date":248,"type":21},"2030-05-01",{"name":41,"class":42},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":74,"sex":17,"minAge":54,"maxAge":187,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":43},"100644409","finding-immune-nascent-type-1-diabetes-100644409","NCT07663136","Finding Immune Nascent Type 1 Diabetes","Finding Immune Nascent Type 1 Diabetes (FIND T1D)","FIND T1D","Inclusion Criteria:\n\n* Participant must be in Indiana Biobank\n* Participant must be able to provide consent\n* Ages 1-99 including pregnant women\n\nExclusion Criteria:\n\n* Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study\n* While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening",{"count":259,"type":21},3800,[24],"The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:\n\nWhat form of recruitment communication is most effective for completing a type 1diabetes home screening kit?\n\nResearchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).\n\nParticipants will be contacted either via email\u002Fmail or by phone and asked if they want to complete a type 1 diabetes home screening kit.",[263,264],"Healthy Adult","Type 1 Diabetes (T1D)",[266,267],"type 1 diabetes home screening kit","type 1 diabetes","2026-06-17",{"date":122,"type":35},{"date":271,"type":21},"2026-06",{"date":273,"type":21},"2029-06",{"name":41,"class":42},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":282,"conditions":283,"keywords":290,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":43},"100242269","pediatric-cardiomyopathy-mutation-analysis-100242269","NCT02432092","Pediatric Cardiomyopathy Mutation Analysis","Inclusion Criteria:\n\n* Subjects with cardiomyopathy\n* Family members of subjects with cardiomyopathy\n\nExclusion Criteria:\n\n* Subjects without cardiomyopathy\n* Family members of subjects without cardiomyopathy",{"count":53,"type":21},"The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.",[284,285,286,287,288,289],"Cardiomyopathies","Dilated Cardiomyopathy","Hypertrophic Cardiomyopathy","Restrictive Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Left Ventricular Non-compaction Cardiomyopathy",[291,292,293,294,295,296,297],"Cardiomegaly","Cardiovascular Diseases","Heart Diseases","Systolic dysfunction","Diastolic dysfunction","Ventricular hypertrophy","Heart failure",{"date":172,"type":35},{"date":300,"type":4},"2014-04",{"date":302,"type":21},"2030-12-31",{"name":41,"class":42},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":43},"100242268","molecular-genetics-of-heterotaxy-and-related-congenital-heart-defects-100242268","NCT02432079","Molecular Genetics of Heterotaxy and Related Congenital Heart Defects","Inclusion Criteria:\n\n* Subjects with heterotaxy and related congenital heart defects\n* Family members of subjects with heterotaxy and related congenital heart defects\n\nExclusion Criteria:\n\n* Subjects without heterotaxy and related congenital heart defects\n* Family members of subjects without heterotaxy and related congenital heart defects",{"count":311,"type":21},2000,"The goal of this study is to obtain specimens and data from individuals and their families with heterotaxy and related congenital heart defects in order to clarify the molecular genetics of this disorder. The knowledge gained from the analysis of this information will provide the basis for future genetic counseling as well as contribute to knowledge about the biology of normal and abnormal development of left-right anatomic asymmetry.",[314,315],"Heterotaxy Syndrome","Congenital Heart Defects",[317,318,319,320,321,292,322,323,324,325,326,327,328,293,329,330,331,332,333,334,335,336,337,338,339],"Abnormalities, Multiple","Asplenia","Bilary Atresia","Birth Defect","Cardiovascular Abnormalities","Congenital Abnormalities","Congenital Heart Disease","Dextrocardia Syndrome","Disturbed Internal Organ Positioning","Genetics","Genetic Testing","Heart Defects, Congenital","Heterotaxy syndrome","Intestinal malrotation","Laterality","Left Atrial Isomerism","Pediatrics","Polysplenia","Right Atrial Isomerism","Splenic Diseases","Cilia","Situs inversus","Dextrocardia",{"date":172,"type":35},{"date":342,"type":4},"2009-07",{"date":344,"type":21},"2030-12",{"name":41,"class":42},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":162,"minAge":18,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":43},"100606397","the-new-empowerment-after-exposure-to-trauma-next-study-100606397","NCT07175025","The New Empowerment After eXposure to Trauma (NEXT) Study","NEXT","Inclusion Criteria:\n\n* 18 years of age or older\n* able to read and speak English\n* diagnosis of probable PTSD as determined by the PTSD Checklist for DSM-5 (PCL-5)\n* pregnant or postpartum (delivered within 12 weeks) at the time of the eligibility screen Exclusion criteria\n* current severe suicide risk as determined by the Columbia Suicide Severity Rating Scale Screener (C-SSRS)\n* current psychotic or manic symptoms as determined by the DIAMOND screener and the Mood Disorder Questionnaire for Bipolar Disorder\n* cognitive impairment\n* concurrent trauma-focused psychotherapy\n* medical advice limiting participation in exposure therapy\n* current legal actions related to trauma\n* does not meet criteria for PTSD\n* not pregnant or delivered more than 12 weeks after timing of eligibility screening","50 Years",{"count":355,"type":21},106,[24],"The NEXT Study is a randomized controlled pilot examining the feasibility and acceptability of a revised perinatal PTSD protocol. This study will randomize perinatal participants with PTSD to receive NET (n=45); treatment group) and will be compared to perinatal women randomized to usual care (n=45; comparator group). The overall objective of this project is to determine the most feasible and acceptable protocol for a brief virtual perinatal PTSD intervention.",[359,360],"PTSD - Post Traumatic Stress Disorder","PTSD (Childbirth-Related)",[362,363,364,365,366],"Pregnancy","Postpartum Period","Narrative Exposure Therapy","Post-Traumatic Stress Disorder","Brief interventions","2026-06-16",{"date":243,"type":35},{"date":370,"type":35},"2025-09-24",{"date":372,"type":21},"2028-07-31",{"name":41,"class":42},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":74,"sex":17,"minAge":353,"maxAge":116,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":392,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":43},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy",{"count":383,"type":21},35,[24],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[387,388,389,390,391],"Salt; Excess","Hypertension","Aging","Inflammation","Blood Pressure",[391,393,389,390,394],"Salt","Cardiovascular Disease",{"date":243,"type":35},{"date":397,"type":35},"2025-03-06",{"date":127,"type":21},{"name":41,"class":42},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":74,"sex":17,"minAge":408,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":43},"100481169","ketone-ester-and-salt-keas-in-young-adults-100481169","NCT05545501","Ketone Ester and Salt (KEAS) in Young Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Young Adults","KEAS","Inclusion Criteria:\n\n* Between the ages of 19-39\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, \\& cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners).\n\nExclusion Criteria:\n\n* High blood pressure - greater than 150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","19 Years","39 Years",{"count":383,"type":21},[24],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs the ability of systemic blood vessels and the kidneys to control blood pressure, which contributes to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. There is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. However, limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could allow us to determine novel therapeutic targets to combat high salt.",[387,388],{"date":243,"type":35},{"date":416,"type":35},"2023-03-24",{"date":127,"type":21},{"name":41,"class":42},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":43},"100620378","palliative-care-for-people-with-hf-100620378","NCT07356843","Palliative Care for People With HF","Implementing Community Palliative Care for People With Heart Failure","Inclusion Criteria:\n\n* Outpatient clinician or staff member (e.g. physician, physician assistant, nurse practitioner, registered nurse, social worker, psychologist, medical assistant) or healthcare leadership personnel (e.g. Chief Nursing Officer, Clinic Medical Director etc.)\n* at least 6 months of experience caring for patients with HF\n* 18 years or older\n\nExclusion Criteria:\n\n\\-",{"count":427,"type":21},20,"Imagine having heart failure, a condition where the heart struggles to pump blood, making daily life hard. People with heart failure often don't feel well and end up going to the hospital a lot. Many of these people could feel better with extra help, but there aren't many programs that offer support beyond usual heart failure treatments. That's where the ADAPT program comes in, which stands for \"Advancing Symptom Alleviation with Palliative Treatment.\" In this program, nurses and social workers call people weekly, helping them manage their toughest symptoms, offering tools to cope with heart failure, and keeping the patients' current doctors involved. We tested this program in a research study with heart failure patients and found that it improved their quality of life and lowered depression, anxiety, and heart failure symptoms. The question now is if the ADAPT program will work in the community, outside of a research setting, so that more people could benefit from it. Specifically, can the ADAPT program work well in new places? Will patients and their families find it helpful? Most importantly, can it help improve the lives of people with heart failure in these new settings? To answer these questions, the study team will work with healthcare providers to 1) ask how to adjust the ADAPT program to work well in various settings (e.g. primary care, heart failure clinic) and 2) use this information to create simple materials and trainings to help them easily provide ADAPT. This will prepare for the next phase of this project to test out the new ADAPT program.",[430,431,432,433],"Congestive Heart Failure","Congestive Heart Failure(CHF)","Congestive Heart Failure (CHF)","Congestive Heart Failure Chronic",{"date":367,"type":35},{"date":436,"type":35},"2025-10-29",{"date":438,"type":21},"2028-09",{"name":41,"class":42},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":455,"locationsCount":456},"100445358","biomarker-of-diabetic-retinopathy-100445358","NCT05079399","Biomarker of Diabetic Retinopathy","Inclusion Criteria:\n\n* Ability to cooperate with imaging procedures.\n* Health status: established type 2 diabetes\n* No history of panretinal photocoagulation (PRP)\n* No history of treatment with intravitreal agents for past 12 months\n\nExclusion Criteria:\n\n* Previous or current malignancy\n* Acute or chronic infection (HIV, hepatitis B or C, tuberculosis)\n* Cerebral vascular accident or cerebral vascular procedure\n* Current pregnancy\n* History of organ transplantation\n* Presence of a graft (to avoid any effect of the graft)\n* History of previous vitrectomy\n* Subjects with a history of age-related macular degeneration age-related macular degeneration (AMD), glaucoma, uveitis, and branched or central vein occlusion.",{"count":447,"type":21},192,"Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen\u002Fnutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.",[450],"Diabetic Retinopathy",{"date":268,"type":35},{"date":453,"type":35},"2022-01-01",{"date":61,"type":21},{"name":41,"class":42},3,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":463,"targetDuration":465,"studyType":55,"phases":4,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":43},"100401172","esophageal-impedance-and-manometry-measurements-and-dysphagia-symptom-scoring-100401172","NCT04503785","Esophageal Impedance and Manometry Measurements and Dysphagia Symptom Scoring","Inclusion Criteria:\n\n* All patients who presented to GI Motility Lab at IU University Hospital for esophageal manometry-impedance and\u002For EndoFLIP\n\nExclusion Criteria:\n\n* Age \\\u003C18 yrs old\n* Unable to communicate verbally with the staff",{"count":464,"type":21},1000,"6 Months","Comparison of manometry measurements and EndoFlip Balloon measurements in patients with dysphagia and a known esophageal diagnosis",[468],"Dysphagia, Esophageal",{"date":367,"type":35},{"date":471,"type":35},"2017-01-17",{"date":127,"type":21},{"name":41,"class":42},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":481,"targetDuration":483,"studyType":55,"phases":4,"briefSummary":484,"conditions":485,"keywords":495,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":43},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388","NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial",{"count":482,"type":21},5000,"10 Years","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[486,487,488,489,490,491,492,493,494],"Eosinophilic Esophagitis","Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Constipation","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[496,497,498,499,500,501,502,488],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating",{"date":367,"type":35},{"date":505,"type":35},"2014-11-01",{"date":507,"type":21},"2026-11",{"name":41,"class":42},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":74,"sex":17,"minAge":465,"maxAge":516,"enrollmentInfo":517,"targetDuration":518,"studyType":55,"phases":4,"briefSummary":519,"conditions":520,"keywords":521,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":530,"locationsCount":43},"100221816","gi-neuromuscular-pathology-prospective-registry-100221816","NCT02165059","GI Neuromuscular Pathology Prospective Registry","Indiana University GI Neuromuscular Pathology Prospective Registry","Inclusion Criteria Study Group:\n\nPatients who are undergoing surgical full-thickness biopsy of the stomach and\u002For proximal jejunum for the clinical evaluation of GI neuromuscular disorder.\n\nInclusion Criteria Control Group:\n\nPatients undergoing esophagectomy, sleeve gastrectomy for obesity, or Roux-en Y gastric bypass Patients undergoing Whipple surgery Patients undergoing transplant surgery\n\nPatients who are organ donors and undergoing surgery\n\nExclusion Criteria Study Group:\n\nContraindication for surgical full-thickness biopsy for any reason. Significant comorbidity due to severe cardiovascular, renal, pulmonary, or liver disease.\n\nSignificant coagulopathy Non-ambulatory patients: bed-ridden, nursing home resident. Pregnant Unable to give own informed consent Prisoners\n\nExclusion Criteria Control Group:\n\nPrior diagnosis of gastroparesis Prior diagnosis of chronic intestinal pseudo-obstruction Unable to give own informed consent if not an organ donor","90 Years",{"count":53,"type":21},"2 Years","In this research study, biopsy samples will be collected to provide more insight into the underlying cause of the motility disorders, help direct further investigation into the cause of the underlying condition, provide future prognosis and predict response to gastric electrical stimulation (GES).",[488],[522,500,501,523,524,525],"Nausea","Bloating","Regurgitation","Retching",{"date":367,"type":35},{"date":528,"type":35},"2013-12-01",{"date":152,"type":21},{"name":41,"class":42},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":539,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":43},"100623798","circulating-tumor-dna-in-stage-i-ii-and-iii-germ-cell-tumors-100623798","NCT07401316","Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors","Inclusion Criteria:\n\n1. ≥ 18 years old at the time of informed consent\n2. Ability to provide written informed consent and HIPAA authorization\n3. Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma.\n\n   Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS.\n4. Archival tissue for germ-cell tumor diagnosis available\n\nExclusion Criteria:\n\n1. Concurrent disease or condition that would make the subject inappropriate for study participation\n2. Any serious medical disorder that would interfere with the subject's safety\n3. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent per treating physician coverage.\n4. Patient is being tested for minimal residual disease with other experimental platforms",{"count":538,"type":21},130,[24],"This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.",[542],"Germ Cell Cancer Metastatic",[544],"ctDNA","2026-06-12",{"date":246,"type":35},{"date":548,"type":35},"2026-06-03",{"date":550,"type":21},"2032-12",{"name":41,"class":42},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":562,"conditions":563,"keywords":566,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":43},"100522353","evaluating-disparities-in-precision-oncology-100522353","NCT06081517","Evaluating Disparities in Precision Oncology","Evaluating Disparities in Precision Oncology: An Observational Trial in the Context of a Real-World Academic Practice Model","EDPO","Inclusion Criteria:\n\n1. Ability to provide written informed consent and HIPAA authorization\n2. Patients must be ≥ 18 years old at the time of consent\n3. Patients who have or are planning to undergo molecular testing as part of their routine cancer care\n\nExclusion Criteria:\n\nN\u002FA",{"count":561,"type":21},10600,"This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.",[564,565],"Metastatic Cancer","Advanced Cancer",[567,568],"Precision Medicine","Disparities",{"date":367,"type":35},{"date":571,"type":35},"2024-01-26",{"date":573,"type":21},"2028-12",{"name":41,"class":42},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":43},"100642917","phase-4-imaging-the-effects-of-netarsudil-rhopressa-on-the-trabecular-meshwork-in-glaucoma-and-ocular-hypertension-100642917","NCT07588152","Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension","Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of ocular hypertension or open-angle glaucoma\n* Eye examination within the past year\n* For glaucoma subjects: structural (optic nerve and\u002For retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma\n* Best-corrected visual acuity of 20\u002F100 or better\n* Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)\n* Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)\n\nExclusion Criteria:\n\n* Known intolerance to netarsudil ophthalmic solution\n* Corneal scarring or active corneal disease that would interfere with imaging\n* Inability to tolerate gonioscopy procedures\n* Females of childbearing potential who are not using effective contraception or are not sterile\n* Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion",{"count":583,"type":21},50,[585],"PHASE4","This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.",[588,589],"Glaucoma","Ocular Hypertension","2026-06-09",{"date":592,"type":35},"2026-06-11",{"date":594,"type":35},"2026-06-05",{"date":596,"type":21},"2028-06",{"name":41,"class":42},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":162,"minAge":18,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":456},"100495834","molecular-mechanisms-associated-with-breast-implant-complications-100495834","NCT05736354","Molecular Mechanisms Associated With Breast Implant Complications","MMABIC","Inclusion Criteria for breast implant subjects:\n\n* Age greater than or equal to 18 years\n* Undergoing removal of breast implant\n* Willing and able to comply with protocol instructions\n\nInclusion Criteria for subjects undergoing breast surgeries (other than implant removal)\n\n* Age greater than or equal to 18 years\n* Undergoing breast surgery\n* Willing and able to comply with protocol instructions\n\nExclusion Criteria:\n\n* Individuals who are deemed unable to understand the procedures, risks, and benefits of the study, (i.e., unable to provide informed consent)\n* Pregnant females\n* Immunodeficiency (HIV\u002FAIDS, SCID)\n* Currently on immunosuppressive medications\n* Prisoners",{"count":464,"type":21},"Bacterial biofilms cause implant failures, chronic inflammation, and immune polarization. The study investigates the possible role of bacterial biofilm as a factor in the etiology of Breast Implant Illness. Three patient cohorts will be studied (A) Subjects with breast implant with BII manifestations (B) Subjects with breast implants without BII manifestations (C) Subjects without breast implants who underwent breast surgery procedure. Blood, surgically discarded tissue, implants, and associated capsules will be collected through this protocol.",[608,609],"Breast Implant; Complications","Infection or Inflammation",{"date":592,"type":35},{"date":612,"type":35},"2021-01-03",{"date":614,"type":21},"2028-06-30",{"name":41,"class":42},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":74,"sex":17,"minAge":624,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":456},"100642586","using-virtual-reality-travel-to-reduce-loneliness-in-older-adults-100642586","NCT07644416","Using Virtual Reality Travel to Reduce Loneliness in Older Adults","Virtual Reality Travel (VRT) as a Loneliness Intervention for Older Adults: A Pilot Randomized Controlled Trial","VRT","Inclusion Criteria:\n\n* Adults aged 65 years or older\n* Express willingness to engage with VR technology\n\nExclusion Criteria:\n\n\\- No self-reported physical, sensory, neurological, or cognitive conditions that would make VR use unsafe or impractical (e.g., uncontrolled seizures, severe vertigo, or significant uncorrected vision\u002Fhearing impairments).","65 Years",{"count":626,"type":21},40,[24],"This study aims to investigate whether and how virtual reality travel (VRT) can reduce loneliness among older adults. It will utilize a mixed-methods research design that combines an randomly assigned experiment with follow-up semi-structured interviews.\n\nThis is a pilot study and it is essential to establish the feasibility and acceptability of the protocol, assess the tolerability of VR technology in this population prior to conducting a full-scale RCT, and generate preliminary effect size estimates to inform future sample size calculations.",[630,631,30,632],"Loneliness","Older Adults (65 Years and Older)","Leisure Activities","2026-06-08",{"date":545,"type":35},{"date":636,"type":21},"2026-06-01",{"date":638,"type":21},"2027-05-30",{"name":41,"class":42},""]